These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12811114)

  • 41. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Policy options to contain healthcare costs: a review and classification.
    Stadhouders N; Koolman X; Tanke M; Maarse H; Jeurissen P
    Health Policy; 2016 May; 120(5):486-94. PubMed ID: 27066728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outpatient drug expenditures and prescription policies for diseases with high cost to the National Health Insurance system in Taiwan.
    Lang HC; Lai MS; Chen GT
    J Formos Med Assoc; 2004 Apr; 103(4):280-5. PubMed ID: 15175823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios.
    Franken MG; Corro Ramos I; Los J; Al MJ
    BMC Fam Pract; 2018 Feb; 19(1):31. PubMed ID: 29454331
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutting healthcare costs without preventable clinical incidents--together we can improve.
    Nicklin W
    Healthc Pap; 2001; 2(1):66-70, discussion 86-9. PubMed ID: 12811161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Value(s) for money? Assessing Romanow and Kirby.
    Kenny N
    Healthc Pap; 2004; 4(4):28-34; discussion 80-4. PubMed ID: 15201526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changing healthcare capital-to-labor ratios: evidence and implications for bending the cost curve in Canada and beyond.
    Nauenberg E
    Int J Health Care Finance Econ; 2014 Dec; 14(4):339-53. PubMed ID: 25129110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of diabetes mellitus on healthcare costs in Italy.
    Giorda CB; Manicardi V; Diago Cabezudo J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-19. PubMed ID: 22098288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of outcomes associated with restricted access to atypical antipsychotics.
    Rajagopalan K; Hassan M; Boswell K; Sarnes E; Meyer K; Grossman F
    Am J Manag Care; 2016 Jun; 22(6):e208-14. PubMed ID: 27355908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
    Counterweight Project Team
    J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug policy: an oxymoron?
    Gray J
    Healthc Pap; 2002; 3(1):56-62; discussion 87-94. PubMed ID: 12811112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulary management of antiulcer drugs: economic considerations.
    Tucker PP; Nash DB
    Pharmacoeconomics; 1994 Apr; 5(4):313-34. PubMed ID: 10147240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Whither seniors' pharmacare: lessons from (and for) Canada.
    Morgan SG; Barer ML; Agnew JD
    Health Aff (Millwood); 2003; 22(3):49-59. PubMed ID: 12757272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The costs of constraint and prospects for health care reform in Canada.
    Tuohy CH
    Health Aff (Millwood); 2002; 21(3):32-46. PubMed ID: 12026002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The cost of schizophrenia: a literature review].
    Charrier N; Chevreul K; Durand-Zaleski I
    Encephale; 2013 May; 39 Suppl 1():S49-56. PubMed ID: 23351935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does expenditure on pharmaceuticals give good value for money?: current evidence and policy implications.
    Coyle D; Drummond M
    Health Policy; 1993 Nov; 26(1):55-75. PubMed ID: 10130847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?
    Towse A
    Health Aff (Millwood); 2003; 22(3):42-5. PubMed ID: 12757270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmaceutical cost containment and innovation in the United States.
    Kane NM
    Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.